TY  - JOUR
T1  - Protein Corona Evolution Can Reverse the Intended Targeting Logic of Nanomedicines
A1  - Emma Wilson
A1  - Frederik De Jong
A1  - Lara Peters
JF  - International Journal of Pharmaceutical Research and Allied Sciences
JO  - Int J Pharm Res Allied Sci
SN  - 2277-3657
Y1  - 2024
VL  - 13
IS  - 2
DO  - 10.51847/AD7Ylc3jc1
SP  - 114
EP  - 124
N2  - Active targeting is commonly designed as though the molecular identity presented by a nanomedicine at administration remains the identity that governs subsequent biological recognition. Protein-corona formation challenges that assumption. Adsorption, exchange, conformational rearrangement, compartment-specific replacement, and intracellular remodeling can alter both access to engineered ligands and exposure of newly acquired protein motifs. The resulting carrier may therefore retain, attenuate, lose, or functionally replace its intended recognition route. This Perspective argues that targeting failure and targeting reversal should not be treated as equivalent. We propose reserving functional reversal for situations in which the designed recognition pathway becomes subordinate while a corona-mediated pathway becomes the operative determinant of uptake, sequestration, transport, or clearance. Evidence from serum-dependent targeting, cerebrospinal-fluid masking, mucosal transport, complement activation, leukocyte sequestration, receptor mapping, and deliberately engineered coronas supports the individual transitions required for such a model, but not a universal reversal mechanism. A spatiotemporal interpretation is therefore needed in which corona state, ligand accessibility, receptor competence, compartment, and carrier fate are evaluated at the same biological decision point. This framing shifts nanomedicine design away from static ligand decoration toward validation of the biological identity actually presented during transport.
UR  - https://ijpras.com/article/protein-corona-evolution-can-reverse-the-intended-targeting-logic-of-nanomedicines-zg87uhqdhoiginv
ER  -